Register for the 2022 PDA/FDA Joint Regulatory Conference – Drug Information Update

Quality Evolution/Technology Revolution: Modern Quality Management Solution

CENTER FOR DRUG EVALUATION AND RESEARCH DIVISION of DRUG INFORMATION Your source for the latest drug information. Know the moment it happens. Register for the 2022 PDA/FDA Joint Regulatory Conference The co-sponsored conference, the FDA, and the Parenteral Drug Association (PDA) will provide opportunities for attendees to learn about current issues relating to manufacturing and quality assurance. The 2022 conference takes place Sept. 12-14 in Washington, D.C. An extensive agenda has been developed to assist companies with current good manufacturing practice (CGMP) compliance, which leads to robust quality and supply. As always, sessions will include expert insights into assuring high manufacturing capability and quality, along with numerous practical case studies. The following are examples of some of the sessions at this conference: Responding effectively to FDA 483s De-risking human error potential through good design Supply chain reliability Sustainable CGMP compliance Facility and equipment lifecycle oversight Quality Risk Management Leveraging beneficial manufacturing innovations Newly issued FDA guidances In addition, highly popular annual sessions will return again this year that include panelists from multiple FDQA Centers, including CGMP Update, Center Director Update, and Lunch with the Regulators. Senior leaders and subject matter experts from both the agency and industry will present at the conference. FDA leaders include multiple Center Directors, the Office of Regulatory Affairs (ORA) Associate Commissioner for Regulatory Affairs (ACRA). These include: Dr. Peter W. Marks, MD, Center Director (CBER) Dr. Steven M. Solomon, MD, Center Director (CVM) Dr. Jacqueline Corrigan-Curay, JD, Deputy Center Director (CDER) Dr. Judith A. McMeekin, ACRA (ORA) Alonza Cruse, Director, Office Pharmaceutical Quality Operations (ORA) Follow this link for the extensive conference agenda and information on registration. Registration and Agenda This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA